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Open-source analysisHeart failure is one of the leading causes of death worldwide [1–4]. Current therapeutic strategies are inefﬁcient
and cannot cure this chronic and debilitating condition [5]. Ultimately, heart transplants are required for patient
survival, but donor organs are scarce in availability and only prolong the life-span of patients for a limited time.
Fibrosis is one of the main pathological features of heart failure [6,7], caused by inappropriate stimulation of
ﬁbroblasts and excessive extracellular matrix production. Therefore, an in-depth understanding of the cardiac ﬁ-
broblast is essential to underpin effective therapeutic treatments for heart failure [5]. Fibroblasts in general have
been an underappreciated cell type, regarded as relatively inert and providing only basic functionality; they are
usually referred to as the ‘biological glue’ of all tissues in the body. However, more recent literature suggests that
they actively participate in organ homeostasis and disease [7,8].
We have recently uncovered a uniquemolecular identity for ﬁbroblasts isolated from the heart [9], expressing a set
of cardiogenic transcription factors that have been previously associated with cardiomyocyte ontogenesis. This sig-
nature suggests that cardiac ﬁbroblasts may be ideal for use in stem cell replacement therapies, as they may retain
the memory of where they derive from embryologically. Our data also revealed that about 90% of ﬁbroblasts from
both tail and heart origins share a cell surface signature that has previously been described for mesenchymal
stem cells (MSCs), raising the possibility that ﬁbroblasts andMSCsmay in fact be the same cell type. Thus, our ﬁnd-
ings carry profound implications for the ﬁeld of regenerativemedicine. Here,we describe detailedmethodology and
quality controls related to the gene expression proﬁling of cardiacﬁbroblasts, deposited at the Gene ExpressionOm-
nibus (GEO) under the accession number GSE50531.We also provide the R code to easily reproduce the data quan-
tiﬁcation and analysis processes.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).e Medicine Institute, Monash
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Experimental design, materials and methods
Mouse usage
Eight-week old C57Bl/6J (http://jaxmice.jax.org/strain/000664.
html) adult male mice were obtained from Monash Animal Services
(MAS) facility, Monash University.
Fibroblast isolation and culture
Animals were humanely killed using CO2 asphyxiation and hearts
were perfused with 20 ml of Hank's Balanced Salt Solution without cal-
cium or magnesium (HBSS-Gibco) using a 20 ml syringe and 26 gaugethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
346 M.B. Furtado et al. / Genomics Data 2 (2014) 345–350needles. For perfusion, the needle was inserted into the left ventricular
chamber, while the right atrial appendage was cut open to allow
blood/buffer exit through the pulmonary circulation. This procedure
removed excess blood from heart chambers. Prior to cell isolation, two
wild-type mouse hearts per sample were ﬁnely minced using surgical
scissors. Whole tails from the same animals were skinned and cut into
2–3 mm pieces. Both tissues were subjected to enzymatic digestion
with 0.05% trypsin/EDTA (Gibco) at 37 °C under agitation for 40 min,
washed in HBSS, cleared using 40 μm cell strainers for Falcon tubes
(BD Biosciences) that retain undigested tissue, spun at 400 g for
5 min, resuspended in cell culture media [DMEM high glucose with
glutamax (Gibco), supplemented with 10% foetal bovine serum (FBS-
Gibco), 1× penicillin/streptomycin (Gibco) and 1× sodium pyruvate
(Gibco)] and plated on 10 cm dishes (BD Biosciences). Next morning,
plates were washed twice in phosphate buffered saline (PBS) without
calcium or magnesium (Gibco) to remove debris. Media changes were
performed every couple of days until day 5, after which cells werela
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Fig. 1.Quality control (QC) analysis for samples used formicroarray. A. Electropherogram show
be clearly seen for all samples and no intermediate peaks, equivalent to degradation products,
heart samples, highlighting 18 s (below 2000 bp band of ladder) and 28 s (below 4000 bp band
marker and small RNAs, respectively. RNA Integrity Number (RIN) scores vary from aminimum
intensity.processed for RNA extraction. Cells were cultured in a humidiﬁed incu-
bator with 5% CO2 at 37 °C.
RNA preparation
Cultured ﬁbroblasts fromheart and tail were processed for total RNA
extraction using the mirVana kit (Ambion) as per manufacturer 's in-
structions. Brieﬂy, 10 cm dishes containing heart or tail ﬁbroblasts
were washed twice in PBS (Gibco) and 500 μl of RNA lysis solution
was added to dishes. Cell scrapers (BD Biosciences) were used to ho-
mogenise cell disruption, after which 1:10 (v/v) of miRNA homogenate
additivewas added. Sampleswere subjected to organic extraction using
acid phenol:chloroform and 1.25 volume of ethanol was added to aque-
ous phases, which were passed through a ﬁlter cartridge, washed in kit
wash solutions 1 and 2 and eluted in 50 μl of pre-heated (95 °C) elution
solution. Following manufacturer's recommendations for total RNA
recovery, we have not enriched samples for small RNAs. All sampless typical plot for high quality total RNA, peaks for 18 s and 28 s ribosomal RNA subunits can
are observed. B. Gel image showing expected migration pattern for intact RNA on tail and
of ladder) ribosomal RNA. Small peaks 25 and 200 nucleotides correspond to the loading
of 0 (degraded) to amaximumof 10 (intact) total RNA. nt— nucleotide; FU— ﬂuorescence
347M.B. Furtado et al. / Genomics Data 2 (2014) 345–350were DNAse digested using DNAseI from the DNA-free kit (Ambion) for
20 min at 37 °C, after which 1:10 (v/v) DNAse inactivation reagent was
added, mixed for 2 min at room temperature and spun down at maxi-
mum speed for 90 s in an Eppendorf centrifuge to pellet inactivation
beads. Samples were transferred into clean tubes and further processed
at the Medical Genomics Facility.
Microarray study design
Three replicate samples were proﬁled per condition (i.e. heart or tail
ﬁbroblasts).
RNA labelling and hybridization
Total RNA from 6 samples (3 tail and 3 heart replicas) was
used for microarray analysis. All samples showed RNA integrity
numbers (RINs) ranging between 9–10, as determined by the 2100
Bioanalyser (Agilent) (Fig. 1). 0.1 μg of total RNAwas used to prepare
Cyanine-3 (Cy3) labelled cRNA for hybridization. For labelling, the
One-Color Low input Quick Amp labelling Kit (Agilent) was used ac-
cording to the manufacturer's instructions, after which labelled RNA
was cleaned using by RNeasy column puriﬁcation (Qiagen). Dye incor-
poration and cRNA yield were determined with the NanoDrop ND-
1000 Spectrophotometer.Raw Signals Average
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Fig. 2.Normalisation and transcriptome-wide comparison between cardiac ﬁbroblasts and tail
and normalisation processing stage: (A) Single-channel signals extracted from Agilent Feature
tion; and (C) quantile normalisation. After normalisation, all samples have identical distribut
genes), the reduction of data points through processing and normalisation (55,821 genes), a
(E) Distribution of the level of gene expression fold-changes within the pool of 3924 differentiFor chip hybridization, 600 ng of Cy3 labelled cRNAs were
fragmented at 60 °C for 30min in a reaction volume of 25 μl containing
1× Agilent Fragmentation buffer and 2× Agilent Gene Expression
Blocking agent. Speciﬁc activities ranging between 16–18 pmol Cy3/μg
cRNA were used for each sample. On completion, 25 μl of 2× HI-RPM
Gene Expression buffer (Agilent) was added. 40 μl of samples were
hybridised on SurePrint G3 Mouse GE 8 × 60 K microarrays (Agilent)
for 17 h at 65 °C in a rotating hybridisation oven (Agilent). Following
hybridisation, microarrays were washed with GE wash buffer 1
(Agilent) for 1 min at room temperature and with GE wash buffer 2 at
37 °C for 1 min. Microarrays were scanned with an Agilent C, DNA mi-
croarray scanner at 3 μmresolution (scan area 61×21.6mm), dye chan-
nel set to green, 20 bit tiff. The scanned images were analysed with
Agilent Feature Extraction Software 11.0.1.1 to obtain background
subtracted and spatially detrended Processed Signal intensities.Data normalisation and analysis
Samples were processed by the Monash Health Translation Precinct
(MHTP) Medical Genomics Facility, and run on Agilent SurePrint G3
mouse gene expression arrays (single colour), followed by analysis
with GeneSpring 12.6, using quantile normalisation with no baseline
transformation, logbase 2. Unpaired T test (p b= 0.05, logFC N= 2.0)
with Benjamini–Hochberg correction was used to ﬁnd differentiallyduplicates Quantile normalisation
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ﬁbroblasts. (A–C) Box-plots of the gene expression data at the end of each pre-processing
Extraction Software; (B) data pre-processing, duplicates averaging and log-2 transforma-
ions. (D) Venn diagram illustrating the initial number of entities in the raw data (62,976
nd ﬁnally the pool of differentially-expressed entities with p-value b 0.05 (3924 genes).
ally-expressed entities.
348 M.B. Furtado et al. / Genomics Data 2 (2014) 345–350expressed genes. These results have been reported in the original article
[9].
For the purpose of improved accessibility, a similar analysis was per-
formed here using an open-source pipeline with R and Bioconductor.
The raw single-channel signals were extracted with Agilent Feature Ex-
traction Software 11.0.1.1. Non-uniform, saturated probes, and popula-
tion outliers were ﬁltered using the default “Compromised” option in
GeneSpring GX12.6 (Agilent), with threshold raw signal of 1.0. At the
end of this process, 6 text ﬁles (.txt) were exported for the data normal-
isation stage. This analysis has been deposited in GEO under the acces-
sion number (to be allocated by GEO) and is linked to the original
samples GSM1220786-91 under accession number GSE50531.
Data normalisationwas performedwith R (http://www.r-project.org)
using the publicly available Bioconductor packages (bioconductor.org)
[10]. Three pre-processing and normalisation steps were performed:
(1) use read.maimage function to extract the gProcesedSignal values
from the GeneSpring exported data ﬁles (Fig. 2A); (2) use avereps.EList
function to average the duplicate spots and log-2 transformation
(Fig. 2B); and (3) use normalizeBetweenArrays function to perform
quantile normalisation on all arrays (Fig. 2C).Table 1.1
List of differentially expressed entities when comparing cardiac ﬁbroblasts to tail ﬁbroblasts (u
Probe 1 0 Gene symbol Log fold change p-Value
A_51_P459944 Tcf21 7.774715027 1.38E-07
A_51_P255699 Mmp3 7.668280653 1.93E-05
A_55_P1982291 Clcal 7.533997026 0.00012796
A_52_P58145 Aldh1a2 7.293188199 2.35E-07
A_51_P265806 Clca2 7.201895798 3.98E-05
A_52_P429876 Tbx20 7.199004006 1.04E-06
A_52_P579531 Pdlim3 6.798017108 3.01E-06
A_55_P2111302 Cp 6.728089433 1.49E-06
A_51_P419637 Dclk3 6.63184125 1.94E-07
A_55_P2017418 Cfh 6.541868044 4.38E-05
A_55_P2028894 Gata4 6.490939109 9.05E-05
A_55_P2108248 Art4 6.471910595 0.00010405
A_51_P110301 C3 6.32871005 0.00039752
A_55_P1970385 6.286227697 3.22E-05
A_52_P614777 Sucnr1 6.074222864 0.00026042
A_55_P2162503 Tbx20 6.001391067 0.00017203
A_55_P1992049 Gucy1a3 5.982102699 0.00028777
A_51_P127297 Hsd11b1 5.953520453 5.85E-07
A_51_P159453 Serpina3n 5.799342267 0.00145534
A_52_P28960 Gdf6 5.688645717 1.73E-06
A_55_P2036240 5.673154478 4.05E-05
A_51_P286748 Frzb 5.607110137 4.68E-05
A_51_P116651 Opt 5.603519237 0.00067503
A_55_P2054854 Art4 5.570955142 0.00336205
A_55_P2038525 C3 5.499803595 5.12E-05
A_55_P2124461 5.433866138 3.25E-06
A_51_P376445 Rhox5 5.334853046 0.00452163
A_55_P2059010 Rbp1 5.268991948 2.76E-06
A_55_P2159485 5.254034014 0.00084844
A_55_P1996973 Gvi n1 5.219003996 0.00589851
A_30_P01023737 5.208384457 1.18E-05
A_55_P2071952 Wdr92 5.164057614 1.34E-05
A_51_P367780 Adamts12 5.153752038 2.08E-05
A_52_P120803 Ankrd1 5.150091794 0.00061576
A_52_P220879 Tgm2 5.097421217 0.00035587
A_55_P2185890 Cfh 5.058590753 1.54E-05
A_55_P1984655 5mtnl2 5.048007589 0.00066022
A_51_P508838 Kcne4 5.041911898 4.91E-06
A_55_P2107785 5.02223357 4.56E-05
A_52_P381484 Spon2 4.995680379 1.40E-06
A_55_P2017413 Gm4788 4.974910672 4.43E-05
A_55_P1964960 IL13 4.957875799 0.00183759
A_51_P334942 Aldh1a1 4.930168491 9.06E-07
A_51_P153423 Fndc1 4.924289787 4.64E-05
A_51_P335460 Scin 4.921316898 3.03E-06
A_55_P2007496 4.888471012 0.00065309
A_52_P796840 Cfhr2 4.807319461 7.84E-06
A_51_P246166 Wfdc18 4.794125063 0.00010262
A_55_P1998811 4.74419517 6.38E-05Differential analysis between cardiac ﬁbroblast and tail ﬁbroblast
samples was performed using the Bioconductor limma package [11],
which applies linear models and differential expression functions to
the transcriptomic data. With 6 normalised arrays having identical
distributions (Fig. 2C), the lmFit function identiﬁes the genes that have
differential expression between 3 cardiac ﬁbroblast samples and 3 tail
ﬁbroblast samples. At a p-value threshold of 0.05, we identiﬁed a pool
of 3924 differentially expressed entities (Fig. 2D). These entities were
used for fold-change calculation (Fig. 2E), revealing 94 strongly up-
regulated entities (16×) and 56 strongly down-regulated entities
(−16×). Tables 1.1 and 1.2 detailed the gene symbols corresponding
to the strongly up- and down-regulated entities, which revealed many
cardiogenic genes, including Tcf21, Tbx20 and Gata4. The R code to
reproduce this analysis is available in GEO.
Discussion
Our goal for the current experimentwas to identify cardiac ﬁbroblast-
speciﬁc genes [1-8]. For this purpose, isolated cells were cultured for
5 days in order to remove carry-over of debris and DNA/RNA from deadp-regulated, fold change N 16×, p b 0.05).
Probe 1 0 Gene symbol Log fold change p-Value
A_51_P215475 Ptprb 4.720490634 0.00037027
A_52_P145415 Ptch2 4.695570013 5.40E-06
A_66_P136813 6030408B16R 4.683599203 0.00010558
A_55_P1982404 Gpm6b 4.641949565 0.00142493
A_55_P2108012 Fam78b 4.616958484 6.96E-05
A_55_P1962305 Plac8 4.595679816 0.00118151
A_52_P266132 Fgl2 4.584599456 0.00088425
A_55_P2088720 4.54706191 2.21E-05
A_55_P2109585 Plekha7 4.539532165 1.74E-06
A_55_P2102769 Abca8a 4.535543021 0.00205118
A_55_P2007495 4.513579208 4.12E-05
A_55_P2029746 4.492855257 1.38E-05
A_55_P2051596 4.477946264 0.0002982
A_51_P468140 Serpind1 4.47050946 0.00126139
A_51_P301998 Fmo2 4.458776979 6.63E-06
A_55_P1974845 Pde1a 4.457633544 3.85E-06
A_55_P2169356 4.456953685 0.00467752
A_55_P1953846 Abca8b 4.450698252 0.00092446
A_55_P1954724 Gm20186 4.412602719 1.39E-05
A_55_P2153783 Fmo1 4.408916363 2.90E-06
A_52_P179068 Gucy1b3 4.403895518 0.00191671
A_55_P1957213 3930401B19R 4.398861887 1.74E-05
A_55_P2026270 Cﬁ 4.390561823 0.00108725
A_55_P2140212 4.366229602 2.05E-05
A_55_P2017347 Krtap11–1 4.326344638 0.00387402
A_55_P2114318 4.31693497 2.77E-05
A_55_P2026547 Gal3st2 4.287884906 0.0001618
A_55_P2162910 Rtn1 4.277702379 0.00013212
A_51_P501248 Sphk1 4.239981128 6.43E-05
A_51_P173709 Gprc5b 4.216740223 0.00086867
A_52_P535484 Gvin1 4.2100439 0.00072863
A_55_P2430367 Zbtb8b 4.180203889 4.91E-06
A_51_P441426 Pf4 4.177619023 0.00022135
A_30_P01020754 4.169537934 5.55E-05
A_51_P503625 Gsta3 4.15056312 0.00017442
A_51_P264695 Crym 4.124721129 0.00368514
A_55_P2048855 Sprr2a2 4.10440044 7.57E-06
A_52_P337259 HeyI 4.0902626 6.83E-06
A_55_P1983858 SeeI 4.076340425 1.99E-05
A_55_P1963463 Gabra3 4.060184936 0.00456924
A_55_P1958165 Ms4a7 4.059035938 3.70E-05
A_55_P2099742 Ccl19 4.034638511 0.00020569
A_55_P2016237 Hand2 4.024649163 1.76E-06
A_52_P472302 Fxyd6 4.021862402 5.70E-06
A_51_P176352 Ndrg2 4.002251368 0.00037256
Table 1.2
List of differentially expressed entities when comparing cardiac ﬁbroblasts and tail ﬁbro-
blasts (down-regulated, fold change b−16×, p b 0.05).
Probe ID Gene symbol Log fold change p-Value
A_52_P401504 Thbs4 −9.592174841 1.22E-07
A_55_P2163033 Hoxb13 −9.413716631 4.47E-07
A_51_P152990 Grem2 −8.848601783 2.76E-08
A_51_P241068 Dkk2 −7.605061419 1.48E-06
A_30_P01024322 −6.845383532 0.00167504
A_51_P339793 111rl1 −6.624788912 2.97E-06
A_30_P01022821 −6.236747352 8.13E-05
A_55_P1977431 Cck −6.210979682 2.50E-05
A_55_P2380806 Gm2115 −6.047107571 1.49E-06
A_55_P1983754 Pcp411 −6.022954787 5.01E-06
A_52_P1092823 lrx1 −5.709918806 7.44E-07
A_30_P01017882 −5.589314885 3.33E-05
A_55_P2125311 Rab3b −5.524900093 5.71E-07
A_55_P2104219 Hoxc13 −5.350209094 1.25E-06
A_30_P01030354 −5.247161242 0.01040968
A_55_P1963807 Actg2 −5.05268315 1.23E-06
A_55_P1959633 Hnf4a −5.01046471 0.0084615
A_51_P431329 Car3 −4.999183138 0.00029175
A_55_P2275437 −4.971382946 0.0001802
A_51_P254425 Ah rr −4.931766401 1.13E-06
A_51_P453909 Cyp2f2 −4.90093426 1.07E-05
A_52_P547612 Tmem30b −4.882588964 3.74E-06
A_55_P1970075 Hoxa13 −4.838619293 1.99E-06
A_30_P01023831 −4.836691283 1.42E-06
A_55_P2035946 Penk −4.821628549 4.05E-06
A_51_P112223 Gsta4 −4.793332842 1.64E-06
A_51_P350817 Cnn1 −4.788691188 1.87E-06
A_30_P01027398 −4.776324333 8.12E-05
A_55_P2126192 Lgr5 −4.678393687 0.00126788
A_51_P309488 1810058N15Ril −4.676510147 3.09E-06
A_51_P253481 Ces1g −4.633576905 0.00024964
A_30_P01019159 −4.60457949 3.24E-05
A_52_P374960 Ostn −4.570737399 0.00132575
A_51_P222337 Rspo2 −4.566245563 0.00010263
A_55_P1984896 Fsip2 −4.54577185 0.00054826
A_55_P2028399 Hoxc11 −4.466924796 3.41E-05
A_55_P2107140 Olfr323 −4.46213166 6.91E-05
A_52_P973575 Hoxb9 −4.442393871 4.66E-05
A_51_P176202 Ankrd36 −4.369381912 0.00103598
A_52_P569375 Fgf5 −4.365217026 0.00794978
A_51_P108183 Tnmd −4.345146004 0.00198834
A_51_P194230 Zic1 −4.320743819 3.29E-05
A_51_P241319 Cilp −4.272317182 0.00206339
A_51_P413111 Ppm1l −4.265754405 3.35E-06
A_51_P215374 Slc6a17 −4.220019679 0.00027602
A_55_P2163659 Rspo3 −4.177589527 0.00011669
A_51_P375754 Hoxc10 −4.165266321 0.00468582
A_55_P2103297 −4.153975645 4.06E-06
A_55_P2001486 −4.137007991 7.49E-05
A_52_P194971 Hoxb7 −4.093762326 0.00026535
A_55_P2360800 C230060E24 −4.071029277 0.00301094
A_51_P516637 Bmp5 −4.058261531 0.00185459
A_55_P2069226 −4.0448526 0.000832
A_55_P2053933 Foxa1 −4.04379596 7.51E-05
A_55_P2014249 Sema3a −4.042700618 0.00119229
A_52_P337126 Bves −4.006299 0.00071079
349M.B. Furtado et al. / Genomics Data 2 (2014) 345–350cardiomyocytes present in fresh preparations. Contamination with
cardiomyocyte structuralmarkers has been reported in previous analyses
[12], as the cell isolation method for compact tissue requires harsh
enzymatic dissociation conditions, which causes extensive cardiomyo-
cyte death. We found that a 5-day passage 0 culture produces non-
conﬂuent, highly healthy cells where no statistically signiﬁcant contami-
nation with cardiomyocyte genes can be detected.
Upon visualisation of the raw data (Fig. 2A), we noticed that sample
Tail2 showed higher overall signal intensity than others. As all samples
were processed simultaneously and showed similar RIN scores (Fig. 1),
we believe this ﬁnding is a technical problem inherent to the hybridiza-
tion step or chip composition.Nevertheless, this discrepancy did not im-
pair our analysis.As with many microarray datasets, data noise is an important issue.
We performed differential analysis using the robust lmFit method,
which is widely regarded as noise-tolerant in the bioinformatics com-
munity. The high-conﬁdence entities evaluated by log fold-change and
p-value (such as the cardiogenic genes Tcf21 and Tbx20) were subse-
quently validated using qPCR validation to conﬁrm their biological rele-
vance, as described by our main research article [9].
The microarray analysis pipeline described here made use of both
the proprietary GeneSpring GX12.6 software and open source R pack-
ages. In addition to our original analysis [9], we have provided a second
open-source analysis to facilitate the reproducibility of our study. Due to
differences between methods (algorithms) provided by limma and
GeneSpring, and the closed-nature of the Genespring software, there
are discrepancies between the ﬁnal fold-change calculations between
the two analyses. However, although the exact values differed for enti-
ties found up- and down-regulated in the open source analysis, our
genes of interest were similarly differentially regulated in both analyses.
A range of bona ﬁde haematopoietic genes were up-regulated
in heart samples, for example Ccl19, Cd28, Mpeg1, Plac8 and Cx3cr1,
while other haematopoietic markers, such as Cd45, Cd31 and Cd34
were not signiﬁcantly altered. Most of these genes have not been corre-
latedwith ﬁbroblast biology yet, although expression ofCx3cr1has been
previously reported in cardiac ﬁbroblasts [13]. We have also not detect-
ed signiﬁcant levels of CD31, CD34 or CD45 protein in our samples [9],
supporting the argument that if present, haematopoietic cells are not
amajor contaminant in our cultures. However, leukocyte contamination
in our cultures cannot be ruled out at this point. As our laboratory
has previously characterised a population of resident macrophages in
the heart [12], follow-up experiments using sorted CD90+, CD45+,
CD31− cells would clarify this issue.
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